Futura provides US regulatory and commercial update for MED3000
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, is pleased to provide an update on good progress with its regulatory and commercial activities for MED3000.
MED3000 is the Company’s breakthrough, topical gel formulation for treatment of erectile dysfunction (“ED”). It has the potential to become the first globally available, clinically proven, over the counter (“OTC”) treatment for erectile dysfunction and has already been approved as the first pan-European topical treatment for ED available without the need of a doctor’s prescription. The USA market is the largest ED market globally and the company’s objective of OTC status for MED3000 continues to be a top priority given its potential to be the first OTC clinically proven treatment for ED.